Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin-Reference-Cited by-同舟云学术

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin

Published:2004 Issue:10 Volume:101 Page:2170-2176
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Delaunoit Thierry,Goldberg Richard M.,Sargent Daniel J.,Morton Roscoe F.,Fuchs Charles S.,Findlay Brian P.,Thomas Sachdev P.,Salim Muhammad,Schaefer Paul L.,Stella Philip J.,Green Erin,Mailliard James A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Cancer Statistics, 2002

2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

3. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.

4. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

5. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current drug therapy for colorectal cancer;Colorectal Cancer;2024

2. Gegen Qinlian standard decoction alleviated irinotecan-induced diarrhea via PI3K/AKT/NF-κB axis by network pharmacology prediction and experimental validation combination;Chinese Medicine;2023-04-27

3. Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer;Contemporary Clinical Trials;2021-06

4. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis;BMC Cancer;2021-02-04

5. The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer;Medicine;2019-09